Record-Breaking Price Movement
On 05 Aug 2026, Fredun Pharmaceuticals Ltd’s stock surged to an intraday high of Rs.1188.45, representing a 7.09% rise from the day’s low of Rs.1084. This peak price not only sets a new 52-week high but also reflects a substantial 20.00% gain on the day, significantly outperforming the Sensex’s modest 0.25% increase. The stock’s performance today also outpaced its sector by 6.6%, underscoring its strong momentum relative to peers.
Consistent Uptrend Over Recent Sessions
The stock has demonstrated a sustained upward trajectory, gaining for six consecutive days and delivering a cumulative return of 30.55% during this period. Over longer time frames, Fredun Pharmaceuticals Ltd has outperformed the broader market by a wide margin. Its one-week return stands at 46.79% compared to the Sensex’s 1.25%, while the one-month gain is 54.32% against the Sensex’s 1.11%. Over three months, the stock has appreciated by 59.00%, dwarfing the Sensex’s 2.09% rise.
Exceptional Long-Term Performance
Fredun Pharmaceuticals Ltd’s stock has delivered extraordinary returns over the past year, rising 270.20% while the Sensex declined by 2.58%. Year-to-date, the stock has gained 153.13%, contrasting with the Sensex’s negative 7.74% performance. Even over a three-year horizon, the company’s shares have appreciated by 263.13%, far exceeding the Sensex’s 19.64% growth. The five-year performance is particularly striking, with an 865.91% increase compared to the Sensex’s 44.29%. These figures highlight the company’s robust market presence and investor confidence over multiple time frames.
Technical Indicators Confirm Bullish Momentum
Technical analysis reveals a strong bullish trend for Fredun Pharmaceuticals Ltd. The current trend, which shifted to bullish on 09 Apr 2026 at a price of Rs.611.58, remains intact. Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory signal bullishness on both weekly and monthly charts. The stock is trading above all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the strength of the upward momentum.
Immediate support is established at Rs.324.00, the 52-week low, while resistance levels previously noted at Rs.934.85 (20 DMA), Rs.767.95 (100 DMA), and Rs.660.54 (200 DMA) have been decisively surpassed. The new 52-week high of Rs.1188.45 now serves as a key reference point for future price action.
Valuation Metrics Reflect Premium Pricing
As of 05 Aug 2026, at 11:51 AM with the stock price at Rs.1,331.70, Fredun Pharmaceuticals Ltd’s valuation multiples indicate a premium market positioning. The price-to-earnings (P/E) ratio stands at 49x, while the price-to-book value (P/BV) is 6.61x. Enterprise value multiples include EV/EBITDA at 21.09x and EV/EBIT at 23.00x, with an EV/Sales ratio of 3.13x. The PEG ratio is 0.85x, suggesting that the stock’s price growth is somewhat aligned with earnings growth expectations.
Dividend metrics show a modest yield of 0.04%, with the latest dividend declared at Rs.0.2333 per share and a payout ratio of 1.15%. The ex-dividend date was 23 Jun 2026.
Quality Assessment Highlights Growth and Moderate Leverage
Fredun Pharmaceuticals Ltd is classified as an average quality company based on long-term financial performance. The company exhibits excellent growth, with a five-year sales compound annual growth rate (CAGR) of 36.42% and a five-year EBIT growth of 59.04%. However, capital structure metrics are below average, with moderate leverage indicated by an average debt-to-EBITDA ratio of 2.93 and net debt-to-equity of 0.56. The average EBIT to interest coverage ratio is 2.57x, reflecting some pressure on interest servicing capacity.
Return on capital employed (ROCE) averages a healthy 15.49%, while return on equity (ROE) is weaker at 12.48%. The company maintains a tax ratio of 20.03% and has no promoter share pledging, which supports financial stability. Institutional holdings remain low at 4.00%.
Recent Financial Trends Show Positive Momentum
Short-term financial trends as of March 2026 are positive. Operating cash flow reached a peak of ₹16.44 crores annually, while profit before tax excluding other income (PBT less OI) grew by 54.96% quarterly to ₹11.25 crores. Quarterly profit after tax (PAT) also hit a high of ₹10.78 crores. Net sales for the quarter were the highest recorded at ₹213.05 crores, with profit before depreciation, interest, and tax (PBDIT) at ₹28.88 crores.
Debt-equity ratio improved to a low of 0.80 times in the half-year period. However, operating profit to interest coverage ratio declined to 1.99 times quarterly, and interest expenses rose to ₹14.49 crores, indicating some pressure on interest costs despite overall positive earnings growth.
Delivery Volumes Reflect Increasing Market Participation
Delivery volumes have shown a marked increase, with a 1-month delivery change of 85.08% and a 1-day delivery change of 19.58% compared to the 5-day average. On 04 Aug 2026, delivery volume was 30.67 thousand shares, accounting for 76.01% of total volume, well above the trailing one-month average of 14.69 thousand shares and previous month average of 7.94 thousand shares. This trend suggests growing market engagement in the stock.
Summary of the Stock’s Journey to New Heights
Fredun Pharmaceuticals Ltd’s ascent to an all-time high price of Rs.1188.45 is the culmination of sustained strong performance across multiple dimensions. The stock’s consistent gains over recent weeks, robust long-term returns, and bullish technical indicators all contribute to this milestone. While valuation multiples reflect a premium, the company’s excellent growth rates and improving financial metrics underpin the market’s recognition of its progress.
Despite moderate leverage and some pressure on interest coverage, the company’s overall financial health remains stable, supported by strong sales growth and improving profitability. The absence of promoter share pledging and increasing delivery volumes further reinforce the stock’s solid standing in the Pharmaceuticals & Biotechnology sector.
Fredun Pharmaceuticals Ltd’s achievement of a new all-time high price marks a significant chapter in its market history, reflecting both its operational strengths and investor confidence in its business fundamentals as of 05 Aug 2026.
